mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels

Cancer Biology and Therapy

Volumn 15, Issue 11, 2014, Pages 1499-1514

  Goudarzi, Kaveh M ^a   Nistér, Monica ^a   Lindström, Mikael S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Actinomycin D; Caffeine; Glioma; mTOR; Nutlin 3; p21; p53; Rapamycin; Ribosomal protein L11; Ribosome biogenesis

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CAFFEINE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; NUCLEOLIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PUMA PROTEIN; RAPAMYCIN; RIBOSOMAL PROTEIN L11; RIBOSOME PROTEIN; SMALL INTERFERING RNA; TEMSIROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN; ANTINEOPLASTIC ANTIBIOTIC; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL NUCLEUS; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; OSTEOSARCOMA; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; NUCLEOLUS; PHYSIOLOGICAL STRESS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEOLUS; CELL PROLIFERATION; DACTINOMYCIN; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MDM2; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; STRESS, PHYSIOLOGICAL; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84918529133     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.955743     Document Type: Article

References (73)

1. Bywater MJ, Pearson RB, McArthur GA, Hannan RD. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer 2013; 13:299-314; PMID:23612459; http://dx.doi.org/10.1038/nrc3496
2. Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood 2010; 115:3196-205; PMID:20194897; http://dx.doi.org/10.1182/blood-2009-10-178129
3. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell.2009.04.037
4. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Rev Cancer 2013; 13:83-96; http://dx.doi.org/10.1038/nrc3430
5. Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010; 29:4253-60; PMID:20498634; http://dx.doi.org/10.1038/onc.2010.189
6. Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2011; 2:234-8; PMID:21406728
7. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009; 16:369-77; PMID:19878869; http://dx.doi.org/10.1016/j.ccr.2009.09.024
8. Zhou X, Liao JM, Liao WJ, Lu H. Scission of the p53-MDM2 loop by ribosomal proteins. Genes & Cancer 2012; 3:298-310; PMID:23150763; http://dx.doi.org/10.1177/1947601912455200
9. Boyd MT, Vlatkovic N, Rubbi CP. The nucleolus directly regulates p53 export and degradation. J Cell Biol 2011; 194:689-703; PMID:21893597; http://dx.doi.org/10.1083/jcb.201105143
10. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004; 279:44475-82; PMID:15308643; http://dx.doi.org/10.1074/jbc.M403722200
11. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004; 24:7669-80; PMID:15314174; http://dx.doi.org/10.1128/MCB.24.17.7669-7680.2004
12. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3:577-87; PMID:12842086; http://dx.doi.org/10.1016/S1535-6108(03)00134-X
13. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003; 23:8902-12; PMID:14612427; http://dx.doi.org/10.1128/MCB.23.23.8902-8912.2003
14. Bursac S, Brdovcak MC, Pfannkuchen M, Orsolic I, Golomb L, Zhu Y, Katz C, Daftuar L, Grabušić K, Vukelić I, et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci U S A 2012; 109:20467-72; PMID:23169665; http://dx.doi.org/10.1073/pnas.1218535109
15. Donati G, Peddigari S, Mercer CA, Thomas G. 5S Ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Reports 2013; 4:87-98; PMID:23831031; http://dx.doi.org/10.1016/j.celrep.2013.05.045
16. Sloan KE, Bohnsack MT, Watkins NJ. The 5S RNP Couples p53 homeostasis to ribosome biogenesis and nucleolar stress. Cell Reports 2013; 5:237-47; PMID:24120868; http://dx.doi.org/10.1016/j.celrep.2013.08.049
17. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindstrom MS, Zhang Y. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 2010; 18:231-43; PMID:20832751; http://dx.doi.org/10.1016/j.ccr.2010.08.007
18. Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI. The nucleolus under stress. Mol Cell 2010; 40:216-27; PMID:20965417; http://dx.doi.org/10.1016/j.molcel.2010.09.024
19. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16:3693-704; PMID:9218810; http://dx.doi.org/10.1093/emboj/16.12.3693
20. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40:310-22; PMID:20965424; http://dx.doi.org/10.1016/j.molcel.2010.09.026
21. Hasty P, Sharp ZD, Curiel TJ, Campisi J. mTORC1 and p53: clash of the gods? Cell Cycle 2013; 12:20-5; PMID:23255104; http://dx.doi.org/10.4161/cc.22912
22. Lai KP, Leong WF, Chau JF, Jia D, Zeng L, Liu H, He L, Hao A, Zhang H, Meek D, et al. S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J 2010; 29:2994-3006; PMID:20657550; http://dx.doi.org/10.1038/emboj.2010.166
23. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harbor Perspectives in Biology 2010; 2: a001057; PMID:20182617; http://dx.doi.org/10.1101/cshperspect.a001057
24. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001; 98:11598-603; PMID:11504915; http://dx.doi.org/10.1073/pnas.181181198
25. Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R, Oren M. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death Differ 2005; 12:1578-87; PMID:15933740; http://dx.doi.org/10.1038/sj.cdd.4401677
26. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008; 22:1728-36; PMID:18548093; http://dx.doi.org/10.1038/leu.2008.158
27. Suvasini R, Somasundaram K. Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy. Oncogene 2010; 29:3605-18; PMID:20418912; http://dx.doi.org/10.1038/onc.2010.123
28. Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 2009; 8:2810-8; PMID:19657224; http://dx.doi.org/10.4161/cc.8.17.9503
29. Burger K, Muhl B, Harasim T, Rohrmoser M, Malamoussi A, Orban M, Kellner M, Gruber-Eber A, Kremmer E, Hölzel M, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 2010; 285:12416-25; PMID:20159984; http://dx.doi.org/10.1074/jbc.M109.074211
30. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; http://dx.doi.org/10.1126/science.1092472
31. Avitabile D, Bailey B, Cottage CT, Sundararaman B, Joyo A, McGregor M, Gude N, Truffa S, Zarrabi A, Konstandin M, et al. Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin. Proc Natl Acad Sci U S A 2011; 108:6145-50; PMID:21444791; http://dx.doi.org/10.1073/pnas.1017935108
32. Sun XX, Dai MS, Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 2007; 282:8052-9; PMID:17242401; http://dx.doi.org/10.1074/jbc.M610621200
33. Sun XX, Dai MS, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 2008; 283:12387-92; PMID:18305114; http://dx.doi.org/10.1074/jbc.M801387200
34. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell cycle 2009; 8:1896-900; PMID:19478560; http://dx.doi.org/10.4161/cc.8.12.8809
35. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013; 123:980-9; PMID:23454761; http://dx.doi.org/10.1172/JCI64099
36. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008; 1:27-36; PMID:19568796; http://dx.doi.org/10.1007/s12154-008-0003-5
37. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, Huang S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res 2009; 69:1000-8; PMID:19176385; http://dx.doi.org/10.1158/0008-5472.CAN-08-2367
38. Cortez D. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem 2003; 278:37139-45; PMID:12847089; http://dx.doi.org/10.1074/jbc.M307088200
39. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 2009; 8:1901-4; PMID:19471118; http://dx.doi.org/10.4161/cc.8.12.8810
40. Reinke A, Chen JC, Aronova S, Powers T. Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. J Biol Chem 2006; 281:31616-26; PMID:16923813; http://dx.doi.org/10.1074/jbc.M603107200
41. Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, Zhu LX, Zhao YF. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-kappaB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IkappaB kinase complex signaling axis in adenoid cystic carcinoma. Mol Pharmacol 2011; 79:106-18; PMID:20959361; http://dx.doi.org/10.1124/mol.110.066910
42. Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun 2011; 406:194-9; PMID:21300025; http://dx.doi.org/10.1016/j.bbrc.2011.02.010
43. Zajkowicz A, Rusin M. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases. Mechanisms of ageing and development 2011; 132:543-51; PMID:21945951; http://dx.doi.org/10.1016/j.mad.2011.09.002
44. Zheng JP, Ju D, Jiang H, Shen J, Yang M, Li L. Resveratrol induces p53 and suppresses myocardin-mediated vascular smooth muscle cell differentiation. Toxicol Lett 2010; 199:115-22; PMID:20797428; http://dx.doi.org/10.1016/j.toxlet.2010.08.010
45. Wanke V, Cameroni E, Uotila A, Piccolis M, Urban J, Loewith R, De Virgilio C. Caffeine extends yeast lifespan by targeting TORC1. Mol Microbiol 2008; 69:277-85; PMID:18513215; http://dx.doi.org/10.1111/j.1365-2958.2008.06292.x
46. Donati G, Bertoni S, Brighenti E, Vici M, Trere D, Volarevic S, Montanaro L, Derenzini M. The balance between rRNA and ribosomal protein synthesis upand downregulates the tumour suppressor p53 in mammalian cells. Oncogene 2011; 30:3274-88; PMID:21399665; http://dx.doi.org/10.1038/onc.2011.48
47. Donati G, Montanaro L, Derenzini M. Ribosome biogenesis and control of cell proliferation: p53 is not alone. Cancer Res 2012; 72:1602-7; PMID:22282659; http://dx.doi.org/10.1158/0008-5472.CAN-11-3992
48. Lindstrom MS, Deisenroth C, Zhang Y. Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions. Cell cycle 2007; 6:434-7; PMID:17329973; http://dx.doi.org/10.4161/cc.6.4.3861
49. Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, Babcock GF, Bernardi R, Pandolfi PP, Thomas G. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nature Cell Biology 2009; 11:501-8; PMID:19287375; http://dx.doi.org/10.1038/ncb1858
50. Fumagalli S, Ivanenkov VV, Teng T, Thomas G. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev 2012; 26:1028-40; PMID:22588717; http://dx.doi.org/10.1101/gad.189951.112
51. Mahata B, Sundqvist A, Xirodimas DP. Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner. Oncogene 2012; 31:3060-71; PMID:22081073; http://dx.doi.org/10.1038/onc.2011.482
52. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120:747-59; PMID:15797377; http://dx.doi.org/10.1016/j.cell.2004.12.040
53. Lindstrom MS, Nister M. Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation. PloS ONE 2010; 5:e9578; PMID:20221446; http://dx.doi.org/10.1371/journal.pone.0009578
54. Liu R, Iadevaia V, Averous J, Taylor PM, Zhang Z, Proud CG. Impairing the production of ribosomal RNA activates mammalian target of rapamycin complex 1 signalling and downstream translation factors. Nucleic Acids Res 2014; 2:5083-96; PMID:24526220; http://dx.doi.org/10.1093/nar/gku130
55. Sundqvist A, Liu G, Mirsaliotis A, Xirodimas DP. Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep 2009; 10:1132-39; PMID:19713960; http://dx.doi.org/10.1038/embor.2009.178
56. Krzesniak M, Zajkowicz A, Matuszczyk I, Rusin M. Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D. Mechanisms of Ageing and Dev 2014; 139:11-21; PMID:24915467; http://dx.doi.org/10.1016/j.mad.2014.06.002
57. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120:681-93; PMID:20197621; http://dx.doi.org/10.1172/JCI40535
58. Renton A, Llanos S, Lu X. Hypoxia induces p53 through a pathway distinct from most DNA-damaging and stress-inducing agents. Carcinogenesis 2003; 24:1177-82; PMID:12807744; http://dx.doi.org/10.1093/carcin/bgg044
59. Lindstrom MS, Wiman KG. Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. Oncogene 2003; 22:4993-5005; PMID:12902982; http://dx.doi.org/10.1038/sj.onc.1206659
60. Chen CS, Ho DR, Chen FY, Chen CR, Ke YD, Su JG. AKT mediates actinomycin D-induced p53 expression. Oncotarget 2014; 5:693-703; PMID:24525337
61. Genolet R, Rahim G, Gubler-Jaquier P, Curran J. The translational response of the human mdm2 gene in HEK293T cells exposed to rapamycin: a role for the 5'-UTRs. Nucleic Acids Research 2011; 39:989-1003; PMID:20876686; http://dx.doi.org/10.1093/nar/gkq805
62. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493:338-45; PMID:23325216; http://dx.doi.org/10.1038/nature11861
63. Liu D, Xu Y. p53, oxidative stress, and aging. Antioxidants Redox Signaling 2011; 15:1669-78; PMID:21050134; http://dx.doi.org/10.1089/ars.2010.3644
64. Qian Y, Chen X. Senescence regulation by the p53 protein family. Methods Mol Biol 2013; 965:37-61; PMID:23296650; http://dx.doi.org/10.1007/978-1-62703-239-1-3
65. Tucci P. Caloric restriction: is mammalian life extension linked to p53? Aging 2012; 4:525-34; PMID:22983298
66. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, Long Y, Zhao J, Pei G. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011; 10:908-11; PMID:21615676; http://dx.doi.org/10.1111/j.1474-9726.2011.00722.x
67. Miwa S, Sugimoto N, Yamamoto N, Shirai T, Nishida H, Hayashi K, Kimura H, Takeuchi A, Igarashi K, Yachie A, et al. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-kappaB and MAPK pathways. Anticancer Res 2012; 32:3643-9; PMID:22993301
68. Rallis C, Codlin S, Bahler J. TORC1 signaling inhibition by rapamycin and caffeine affect lifespan, global gene expression and cell proliferation of fission yeast. Aging Cell 2013; 12:563-73; PMID:23551936; http://dx.doi.org/10.1111/acel.12080
69. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological reviews 1999; 51:83-133; PMID:10049999
70. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392-5; PMID:19587680
71. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Science translational medicine 2014; 6:221ra15; PMID:24477002; http://dx.doi.org/10.1126/scitranslmed.3007653
72. Nister M, Heldin CH, Westermark B. Clonal variation in the production of a platelet-derived growth factor-like protein and expression of corresponding receptors in a human malignant glioma. Cancer Res 1986; 46:332-40; PMID:2998609
73. Ge H, Ni S, Wang X, Xu N, Liu Y, Wang L, Wang L, Song D, Song Y, Bai C. Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer. PloS ONE 2012; 7:e51821; PMID:23272171; http://dx.doi.org/10.1371/journal.pone.0051821